Select a profile:

• APP Pharmaceuticals
  • abeo
  • Ambu
  • Anesthesia Business Consultants
  • Arizant Healthcare Inc., a 3M Company
  • BMEYE
  • CompONE Services, Ltd.
  • Dräger
  • Edwards Lifesciences
  • GE Healthcare
  • KARL STORZ Endoscopy-America, Inc.
  • LMA North America
  • Masimo Corporation
  • McKesson
  • McMahon Publishing
  • Mindray
  • Sheridan Healthcare, Inc.
  • Verathon Medical
  • Zotec Partners
  •  

APP Pharmaceuticals

A Responsive Leader in Anesthesia and Analgesia

APP Pharmaceuticals’ commitment to the clinical specialty of anesthesia is reflected in the breadth of its product portfolio and the company’s rapid response to meeting the clinical needs of its customers. This was especially evident during the propofol shortage. As other manufacturers experienced recalls of generic propofol injection, which resulted in manufacturing interruptions, APP recognized the vital clinical importance of maintaining a consistent supply of this important and essential drug. The company acted decisively to increase production of APP Diprivan^® (propofol 1%) and APP Propofol 1% (authorized generic Diprivan^®) at the onset of this critical market shortage to help stabilize product supply. In addition, APP supplemented supply by importing international Fresenius Propoven 1% (propofol 1%) in agreement with the FDA. Fresenius Propoven 1% (propofol 1%) is manufactured in FDA-compliant facilities by APP’s parent company, Fresenius Kabi, the leading manufacturer of propofol injection in the world. Working together, the two companies have combined their efforts and are focused on increasing propofol supply by bringing new capacity on line. As a result, APP is producing at levels to supply the entire U.S. market.

Through its immediate actions, ongoing communication with pharmacies and physicians, and expedited manufacturing and shipping processes, APP is committed to helping ensure continual access to this important and essential drug.

A Broad, Growing Anesthesia and Analgesia Portfolio

APP Pharmaceuticals offers an extensive portfolio of products that continues to grow based on the evolving practice of anesthesia and pain management. As the number of overall clinical procedures continues to shift from inpatient to outpatient settings, APP’s products remain in step with the changing dynamics of anesthesia and pain management.

The most prominent brands of the APP anesthesia and analgesia portfolio are Naropin^® (ropivacaine) and the Diprivan (propofol) family of products. APP is the sole U.S. supplier of Naropin, a unique brand with distinct clinical benefits.^1-3 APP also offers an array of propofol products, including APP Diprivan^® (propofol 1%) and APP Propofol 1% (authorized generic Diprivan^®), both with patented formulations that include ethylenediaminetetraacetic acid (EDTA).

As a supplier of both multisource and branded products, APP brings convenience, efficiency and value to the supply chain process by offering a comprehensive selection of anesthesia and analgesia products, including:

• Astramorph^® (morphine)
• EMLA (lidocaine/prilocaine)
• Flumazenil Injection



• Midazolam Hydrochloride Injection
• Neostigmine Methysulfate Injection
• Nesacaine^® (chloroprocaine)
• Polocaine^® (mepivacaine)
• Sensorcaine^® (bupivacaine)
• Sumatriptan Succinate Injection
• Xylocaine^® (lidocaine)

Global Health Care Resources

APP Pharmaceuticals’ comprehensive product portfolio also includes anti-infective, critical care and oncology pharmaceutical products. With more than 120 marketed products in 400 dosage forms, APP’s products are used in hospitals, long-term care facilities, alternate care sites and clinics throughout North America.

In 2008, Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. As a leading provider of infusion therapy and clinical nutrition in Europe, Latin America and Asia Pacific, Fresenius Kabi’s core product range includes infusion solutions, blood volume substitutes, IV drugs and parenteral and enteral nutrition, as well as medical devices. The company also provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy “caring for life” and a comprehensive product portfolio, Fresenius Kabi aims at improving the quality of life of critically and chronically ill patients all over the world.

A Trusted Partner

APP Pharmaceuticals continues to meet the clinical needs of pharmacists and physicians through the manufacture and distribution of high-quality, cost-effective injectable pharmaceutical products. In anesthesiology, APP has demonstrated this commitment through its collaboration with the medical community and the FDA. In addition, as a trusted partner, clinicians can be assured that APP’s commitment to excellence and value also remains strong in the therapeutic areas of infectious disease, critical care and oncology.

Through the continuous expansion of its broad portfolio of products, APP Pharmaceuticals is dedicated to providing ongoing, affordable health care to patients throughout the country.

References

1. Beaulieu P, Babin D, Hemmerling T. The pharmacodynamics of ropivacaine and bupivacaine in combined sciatic and femoral nerve blocks for total knee arthroplasty. Anesth Analg 2006;103:768-774.
2. Bertini L, Tageriello V, Mancini S, et al. 0.75% and 0.5% ropivacaine for axillary brachial plexus block: a clinical comparison with 0.5% bupivacaine. Reg Anesth Pain Med 1999;24:514-518.
3. Writer WDR, Stienstra R, Eddleston JM, et al. Neonatal outcome and mode of delivery after epidural analgesia for labour with ropivacaine and bupivacaine: a prospective meta-analysis. Br J Anaesth 1998;81:713-717.

This corporate profile was reviewed and approved by APP Pharmaceuticals.

Close